News
Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy
Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)
